Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ocular Therapeutix (OCUL) Other financing activities (2021)

Ocular Therapeutix has reported Other financing activities over the past 2 years, most recently at $275000.0 for Q1 2021.

For Q1 2021, Other financing activities changed N/A year-over-year to $275000.0; the TTM value through Dec 2021 reached $275000.0, changed N/A, while the annual FY2023 figure was $5.2 million, N/A changed from the prior year.
Other financing activities for Q1 2021 was $275000.0 at Ocular Therapeutix, up from $6000.0 in the prior quarter.
Over five years, Other financing activities peaked at $275000.0 in Q1 2021 and troughed at $275000.0 in Q1 2021.